Prostaglandin D 2 receptor antagonists in allergic disorders: safety, efficacy, and future perspectives
The DOI matches its Crossref record; 153 of the 153 references it cites were found in a registry or an index.
Abstract
Introduction: Prostaglandin D2 (PGD2) is a major cyclooxygenase mediator that is synthesized by activated human mast cells and other immune cells. The biological effects of PGD2 are mediated by D-prostanoid (DP1), DP2 (CRTH2) and thromboxane prostanoid (TP) receptors that are expressed on several immune and non-immune cells involved in allergic inflammation. PGD2 exerts various proinflammatory effects relevant to the pathophysiology of allergic disorders. Several selective, orally active, DP2 receptor antagonists and a small number of DP1 receptor antagonists are being developed for the treatment of allergic disorders.Areas covered: The role of DP2 and DP1 receptor antagonists in the treatment of asthma and allergic rhinitis.Expert opinion: Head-to-head studies that compare DP1 antagonists with the standard treatment for allergic rhinitis are necessary to verify the role of these novel drugs as mono- or combination therapies. Further clinical trials are necessary to verify whether DP2 antagonists as monotherapies or, more likely, as add-on therapies, will be effective for the treatment of different phenotypes of adult and childhood asthma. Long-term studies are necessary to evaluate the safety of targeted anti-PGD2 treatments.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prostaglandin D2 and its receptor (PGDR2/CRTH2) play an important role in the generation of inflammation151.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [151]
Citations
Cites
Asthma phenotypes: the evolution from clinical to molecular approaches
Wenzel, S. E. (2012) · Nature Medicine · doi:10.1038/nm.2678 · Cited by 2,412
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Ortega, H. G., Liu, M. C., Pavord, I. D., Brusselle, G. G., FitzGerald, J. M., Chetta, A., Humbert, M., Katz, L. E., Keene, O. N., Yancey, S. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403290 · Cited by 2,322 · cited 1×
“For example, blood eosinophilia or Th2 overexpression are used to select patients candidates for treatment with mAbs anti-IL-5/IL-5Rα [5,8,10,15] or anti-IL-4Rα [16,17].”
BackgroundPavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
Castro, M., Corren, J., Pavord, I. D., Maspero, J., Wenzel, S., Rabe, K. F., Busse, W. W., Ford, L., Sher, L., FitzGerald, J. M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804092 · Cited by 1,986 · cited 3×
“[16,17] have been shown effective in Th2 phenotypes of severe asthma.”
BackgroundLambrecht, B. N., & Hammad, H. (2015) · Nature Immunology · doi:10.1038/ni.3049 · Cited by 1,673 · cited 1×
“Bronchial asthma and allergic rhinitis are common chronic clinical conditions that affect more than 30% of adults in industrialized societies [1,2].”
BackgroundOral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Bel, E. H., Wenzel, S. E., Thompson, P. J., Prazma, C. M., Keene, O. N., Yancey, S. W., Ortega, H. G., & Pavord, I. D. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403291 · Cited by 1,661 · cited 1×
“For example, blood eosinophilia or Th2 overexpression are used to select patients candidates for treatment with mAbs anti-IL-5/IL-5Rα [5,8,10,15] or anti-IL-4Rα [16,17].”
BackgroundType 2 inflammation in asthma — present in most, absent in many
Fahy, J. V. (2015) · Nature Reviews Immunology · doi:10.1038/nri3786 · Cited by 1,654 · cited 1×
“Asthma is a highly heterogeneous inflammatory disorder [80] that results from the interplay between multiple environmental”
BackgroundBleecker, E. R., FitzGerald, J. M., Chanez, P., Papi, A., Weinstein, S. F., Barker, P., Sproule, S., Gilmartin, G., Aurivillius, M., Werkström, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31324-1 · Cited by 1,406
FitzGerald, J. M., Bleecker, E. R., Nair, P., Korn, S., Ohta, K., Lommatzsch, M., Ferguson, G. T., Busse, W. W., Barker, P., Sproule, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31322-8 · Cited by 1,397 · cited 4×
“Monoclonal antibodies targeting IL-5 [5,7–12], IL-5Rα [13,14] or IL-4Rα (i.e., dupilumab) [16,17] have been shown effective in Th2 phenotypes of severe asthma.”
InfluentialLessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344 · cited 1×
“patients with moderate-to-severe asthma stabilized on ICS and long-acting β2-adrenergic receptor agonists failed to meet the primary endpoint and it was discontinued [119].”
BackgroundWheezing Rhinovirus Illnesses in Early Life Predict Asthma Development in High-Risk Children
Jackson, D. J., Gangnon, R. E., Evans, M. D., Roberg, K. A., Anderson, E. L., Pappas, T. E., Printz, M. C., Lee, W.-M., Shult, P. A., Reisdorf, E., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200802-309oc · Cited by 1,317 · cited 1×
“are associated with the onset, progression, and acute exacerbations of asthma particularly in children [154,155].”
BackgroundEfficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
Rabe, K. F., Nair, P., Brusselle, G., Maspero, J. F., Castro, M., Sher, L., Zhu, H., Hamilton, J. D., Swanson, B. N., Khan, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804093 · Cited by 1,184 · cited 3×
“[16,17] have been shown effective in Th2 phenotypes of severe asthma.”
BackgroundThe safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
Hirai, H., Tanaka, K., Yoshie, O., Ogawa, K., Kenmotsu, K., Takamori, Y., Ichimasa, M., Sugamura, K., Nakamura, M., Takano, S., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.2.255 · Cited by 1,099 · cited 8×
“This receptor is expressed on several immune cells such as human basophils [43–47], eosinophils [43,48,49], innate lymphoid cells”
BackgroundInfluentialOral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma
Nair, P., Wenzel, S., Rabe, K. F., Bourdin, A., Lugogo, N. L., Kuna, P., Barker, P., Sproule, S., Ponnarambil, S., & Goldman, M. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1703501 · Cited by 1,044 · cited 1×
“For example, blood eosinophilia or Th2 overexpression are used to select patients candidates for treatment with mAbs anti-IL-5/IL-5Rα [5,8,10,15] or anti-IL-4Rα [16,17].”
BackgroundMAST CELLS AS “TUNABLE” EFFECTOR AND IMMUNOREGULATORY CELLS: Recent Advances
Galli, S. J., Kalesnikoff, J., Grimbaldeston, M. A., Piliponsky, A. M., Williams, C. M. M., & Tsai, M. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141025 · Cited by 1,017 · cited 1×
“disorders [58–60], but are also involved in autoimmune disorders [61], microbial infections [62,63], cardiovascular diseases [64,65],”
BackgroundChupp, G. L., Bradford, E. S., Albers, F. C., Bratton, D. J., Wang-Jairaj, J., Nelsen, L. M., Trevor, J. L., Magnan, A., & ten Brinke, A. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30125-x · Cited by 599 · cited 1×
“For example, blood eosinophilia or Th2 overexpression are used to select patients candidates for treatment with mAbs anti-IL-5/IL-5Rα [5,8,10,15] or anti-IL-4Rα [16,17].”
BackgroundProstaglandin D2 generation after activation of rat and human mast cells with anti-IgE.
Lewis, R. A., Soter, N. A., Diamond, P. T., Austen, K. F., Oates, J. A., & Roberts, L. J. (1982) · The Journal of Immunology · doi:10.4049/jimmunol.129.4.1627 · Cited by 584 · cited 2×
“PGD2 is the main cyclooxygenase product of activated human mast cells [21,23,69].”
BackgroundCarretero, R., Sektioglu, I. M., Garbi, N., Salgado, O. C., Beckhove, P., & Hämmerling, G. J. (2015) · Nature Immunology · doi:10.1038/ni.3159 · Cited by 501
Xue, L., Salimi, M., Panse, I., Mjösberg, J. M., McKenzie, A. N. J., Spits, H., Klenerman, P., & Ogg, G. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.10.056 · Cited by 475 · cited 7×
“type 2 (ILC2s) [50,51], macrophages [52], DCs [53], mast cells [41], monocytes [54], and Th2 cells [43].”
BackgroundInfluentialRelease of Prostaglandin D2into Human Airways during Acute Antigen Challenge
Murray, J. J., Tonnel, A. B., Brash, A. R., Roberts, L. J., Gosset, P., Workman, R., Capron, A., & Oates, J. A. (1986) · New England Journal of Medicine · doi:10.1056/nejm198609253151304 · Cited by 469 · cited 2×
“PGD2 is a potent bronchoconstrictor of human airways and potentiates airway responsiveness to histamine [70,71] and its concentrations are increased in severe asthma compared with mild and moderate asthma [72–74].”
BackgroundReslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels
Bjermer, L., Lemiere, C., Maspero, J., Weiss, S., Zangrilli, J., & Germinaro, M. (2016) · Chest · doi:10.1016/j.chest.2016.03.032 · Cited by 426
Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma
Corren, J., Weinstein, S., Janka, L., Zangrilli, J., & Garin, M. (2016) · Chest · doi:10.1016/j.chest.2016.03.018 · Cited by 388
Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor
Monneret, G., Gravel, S., Diamond, M., Rokach, J., & Powell, W. S. (2001) · Blood · doi:10.1182/blood.v98.6.1942 · Cited by 326 · cited 4×
“Activation of DP2 is also involved in the recruitment and activation of human eosinophils [25,26,43,48,49] and basophils”
BackgroundInfluentialAre Mast Cells MASTers in Cancer?
Varricchi, G., Galdiero, M. R., Loffredo, S., Marone, G., Iannone, R., Marone, G., & Granata, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00424 · Cited by 323
Self-citationAntagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases
Pettipher, R., Hansel, T. T., & Armer, R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2266 · Cited by 317 · cited 2×
“Engagement of DP2 receptor results in the inhibitory G-protein (Gi) with subsequent increased intracellular calcium level and reduced adenylyl cyclase activity and intracellular cAMP concentration [40,57].”
BackgroundNagata, K., Hirai, H., Tanaka, K., Ogawa, K., Aso, T., Sugamura, K., Nakamura, M., & Takano, S. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01251-x · Cited by 297 · cited 1×
“[43,82,83] that play a role in different phenotypes of asthma [60,84,85].”
BackgroundBalzar, S., Fajt, M. L., Comhair, S. A. A., Erzurum, S. C., Bleecker, E., Busse, W. W., Castro, M., Gaston, B., Israel, E., Schwartz, L. B., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201002-0295oc · Cited by 293
Lugogo, N., Domingo, C., Chanez, P., Leigh, R., Gilson, M. J., Price, R. G., Yancey, S. W., & Ortega, H. G. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.07.010 · Cited by 283
Eosinophils: The unsung heroes in cancer?
Varricchi, G., Galdiero, M. R., Loffredo, S., Lucarini, V., Marone, G., Mattei, F., Marone, G., & Schiavoni, G. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1393134 · Cited by 280 · cited 1×
“[43,82,83] that play a role in different phenotypes of asthma [60,84,85].”
BackgroundSelf-citationHypersensitivity reactions to therapeutic monoclonal antibodies: Phenotypes and endotypes
Isabwe, G. A. C., Garcia Neuer, M., de las Vecillas Sanchez, L., Lynch, D.-M., Marquis, K., & Castells, M. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.02.018 · Cited by 265
Liu, M. C., Bleecker, E. R., Lichtenstein, L. M., Kagey-Sobotka, A., Niv, Y., McLemore, T. L., Permutt, S., Proud, D., & Hubbard, W. C. (1990) · American Review of Respiratory Disease · doi:10.1164/ajrccm/142.1.126 · Cited by 247
Gonem, S., Berair, R., Singapuri, A., Hartley, R., Laurencin, M. F. M., Bacher, G., Holzhauer, B., Bourne, M., Mistry, V., Pavord, I. D., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30179-5 · Cited by 247
Patella, V., Marinò, I., Arbustini, E., Lamparter-Schummert, B., Verga, L., Adt, M., & Marone, G. (1998) · Circulation · doi:10.1161/01.cir.97.10.971 · Cited by 246 · cited 1×
“disorders [58–60], but are also involved in autoimmune disorders [61], microbial infections [62,63], cardiovascular diseases [64,65],”
BackgroundSelf-citationGervais, F. G., Cruz, R. P. G., Chateauneuf, A., Gale, S., Sawyer, N., Nantel, F., Metters, K. M., & O'Neill, G. P. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.119919 · Cited by 239 · cited 4×
“Activation of DP2 is also involved in the recruitment and activation of human eosinophils [25,26,43,48,49] and basophils”
BackgroundInfluentialZhu, Z., Lee, P. H., Chaffin, M. D., Chung, W., Loh, P.-R., Lu, Q., Christiani, D. C., & Liang, L. (2018) · Nature Genetics · doi:10.1038/s41588-018-0121-0 · Cited by 239
Arachidonic acid metabolism in purified human lung mast cells.
Peters, S. P., MacGlashan, D. W., Schulman, E. S., Schleimer, R. P., Hayes, E. C., Rokach, J., Adkinson, N. F., & Lichtenstein, L. M. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.132.4.1972 · Cited by 235
Urade, Y., Ujihara, M., Horiguchi, Y., Ikai, K., & Hayaishi, O. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.9.2982 · Cited by 219 · cited 5×
“PGD2 is also elaborated by activated dendritic cells (DCs) [29], macrophages [30], eosinophils [31], T helper type 2 (Th2 cells) [32], endothelial cells [33,34], and platelets [35,36].”
BackgroundInfluentialBarnes, N., Pavord, I., Chuchalin, A., Bell, J., Hunter, M., Lewis, T., Parker, D., Payton, M., Collins, L. P., Pettipher, R., et al. (2012) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2011.03813.x · Cited by 218 · cited 1×
“) in moderate persistent asthmatics demonstrated a small but significant increase in FEV1 after 7 weeks of treatment (200 mg twice daily) [135].”
BackgroundActivation of the Prostaglandin D2 Receptor DP2/CRTH2 Increases Allergic Inflammation in Mouse
Spik, I., Brénuchon, C., Angéli, V., Staumont, D., Fleury, S., Capron, M., Trottein, F., & Dombrowicz, D. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.6.3703 · Cited by 213 · cited 1×
“PGD2 administration increases eosinophilic lung inflammation in ovalbumin challenged mice [77].”
BackgroundTait Wojno, E. D., Monticelli, L. A., Tran, S. V., Alenghat, T., Osborne, L. C., Thome, J. J., Willis, C., Budelsky, A., Farber, D. L., & Artis, D. (2015) · Mucosal Immunology · doi:10.1038/mi.2015.21 · Cited by 213 · cited 7×
“type 2 (ILC2s) [50,51], macrophages [52], DCs [53], mast cells [41], monocytes [54], and Th2 cells [43].”
BackgroundInfluentialA Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma
Bagnasco, D., Ferrando, M., Varricchi, G., Passalacqua, G., & Canonica, G. W. (2016) · International Archives of Allergy and Immunology · doi:10.1159/000447692 · Cited by 212 · cited 1×
“The above findings imply that a phenotyping approach is necessary to identify patient subgroups candidate to targeted therapies [143,150].”
BackgroundSelf-citationProstaglandin D2 pathway upregulation: Relation to asthma severity, control, and TH2 inflammation
Fajt, M. L., Gelhaus, S. L., Freeman, B., Uvalle, C. E., Trudeau, J. B., Holguin, F., & Wenzel, S. E. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.01.035 · Cited by 211 · cited 1×
“and epithelial cells were found in the airways of severe asthmatic patients compared to healthy controls [55,74].”
BackgroundThymic Stromal Lymphopoietin Isoforms, Inflammatory Disorders, and Cancer
Varricchi, G., Pecoraro, A., Marone, G., Criscuolo, G., Spadaro, G., Genovese, A., & Marone, G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01595 · Cited by 208 · cited 1×
“asthma [27,28], induce PGD2 production from human mast cells [24].”
BackgroundSelf-citationCutting edge: differential production of prostaglandin D2 by human helper T cell subsets
Tanaka, K., Ogawa, K., Sugamura, K., Nakamura, M., Takano, S., & Nagata, K. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.5.2277 · Cited by 204 · cited 2×
“PGD2 can also be produced by activated Th2 cells [32], DCs [29], macrophages [30], eosinophils [31], endothelial cells [33,34], and platelets [35,36].”
BackgroundLucarini, V., Ziccheddu, G., Macchia, I., La Sorsa, V., Peschiaroli, F., Buccione, C., Sistigu, A., Sanchez, M., Andreone, S., D'Urso, M. T., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1317420 · Cited by 199
Nasal challenge with ragweed pollen in hay fever patients. Effect of immunotherapy.
Creticos, P. S., Adkinson, N. F., Kagey-Sobotka, A., Proud, D., Meier, H. L., Naclerio, R. M., Lichtenstein, L. M., & Norman, P. S. (1985) · Journal of Clinical Investigation · doi:10.1172/jci112233 · Cited by 198 · cited 1×
“Several investigators have confirmed the original observation [86] that nasal challenge with allergen in patients with seasonal allergic rhinitis (SAR) induces the release of PGD2 [87–89].”
BackgroundHaldar, P., Brightling, C. E., Singapuri, A., Hargadon, B., Gupta, S., Monteiro, W., Bradding, P., Green, R. H., Wardlaw, A. J., Ortega, H., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.11.026 · Cited by 185
Buchheit, K. M., Cahill, K. N., Katz, H. R., Murphy, K. C., Feng, C., Lee-Sarwar, K., Lai, J., Bhattacharyya, N., Israel, E., Boyce, J. A., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.10.020 · Cited by 184 · cited 2×
“asthma [27,28], induce PGD2 production from human mast cells [24].”
BackgroundWenzel, S. E., Westcott, J. Y., Smith, H. R., & Larsen, G. L. (1989) · American Review of Respiratory Disease · doi:10.1164/ajrccm/139.2.450 · Cited by 181 · cited 1×
“The concentration of PGD2 rapidly increases following allergen challenge in patients with asthma [70,75] and the immunologic challenge of human lung tissue rapidly releases PGD2 [76].”
BackgroundMast cells in asthma – state of the art
Bradding, P., & Arthur, G. K. (2015) · Clinical & Experimental Allergy · doi:10.1111/cea.12675 · Cited by 180
Varricchi, G., Bagnasco, D., Borriello, F., Heffler, E., & Canonica, G. W. (2016) · Current Opinion in Allergy & Clinical Immunology · doi:10.1097/aci.0000000000000251 · Cited by 177
Self-citationHolgate, S. T., Burns, G. B., Robinson, C., & Church, M. K. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.4.2138 · Cited by 167 · cited 1×
“PGD2 is the main cyclooxygenase product of activated human mast cells [21,23,69].”
BackgroundThe roles of the prostaglandin D2receptors DP1and CRTH2 in promoting allergic responses
Pettipher, R. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707488 · Cited by 167 · cited 1×
“The DP1 receptor is present on the nasal vasculature and in mucin- secreting cells resulting in tissue swelling and increased nasal airway resistance [38].”
BackgroundLipopolysaccharide Induces Macrophage Migration via Prostaglandin D2 and Prostaglandin E2
Tajima, T., Murata, T., Aritake, K., Urade, Y., Hirai, H., Nakamura, M., Ozaki, H., & Hori, M. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.137992 · Cited by 161
Gosset, P., Bureau, F., Angeli, V., Pichavant, M., Faveeuw, C., Tonnel, A.-B., & Trottein, F. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.10.4943 · Cited by 152 · cited 6×
“PGD2 is also elaborated by activated dendritic cells (DCs) [29], macrophages [30], eosinophils [31], T helper type 2 (Th2 cells) [32], endothelial cells [33,34], and platelets [35,36].”
BackgroundInfluentialHuman mast cells and basophils—How are they similar how are they different?
Varricchi, G., Raap, U., Rivellese, F., Marone, G., & Gibbs, B. F. (2018) · Immunological Reviews · doi:10.1111/imr.12627 · Cited by 151 · cited 2×
“[43,82,83] that play a role in different phenotypes of asthma [60,84,85].”
BackgroundSelf-citationCamacho, M., López-Belmonte, J., & Vila, L. (1998) · Circulation Research · doi:10.1161/01.res.83.4.353 · Cited by 147 · cited 2×
“PGD2 can also be produced by activated Th2 cells [32], DCs [29], macrophages [30], eosinophils [31], endothelial cells [33,34], and platelets [35,36].”
BackgroundHeightened response of eosinophilic asthmatic patients to the CRTH 2 antagonist OC 000459
Pettipher, R., Hunter, M. G., Perkins, C. M., Collins, L. P., Lewis, T., Baillet, M., Steiner, J., Bell, J., & Payton, M. A. (2014) · Allergy · doi:10.1111/all.12451 · Cited by 132
Mast cells in human and experimental cardiometabolic diseases
Shi, G., Bot, I., & Kovanen, P. T. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.117 · Cited by 125 · cited 1×
“disorders [58–60], but are also involved in autoimmune disorders [61], microbial infections [62,63], cardiovascular diseases [64,65],”
BackgroundTaba, Y., Sasaguri, T., Miyagi, M., Abumiya, T., Miwa, Y., Ikeda, T., & Mitsumata, M. (2000) · Circulation Research · doi:10.1161/01.res.86.9.967 · Cited by 123
Kupczyk, M., & Kuna, P. (2017) · Drugs · doi:10.1007/s40265-017-0777-2 · Cited by 123
Staiano, R. I., Loffredo, S., Borriello, F., Iannotti, F. A., Piscitelli, F., Orlando, P., Secondo, A., Granata, F., Lepore, M. T., Fiorelli, A., et al. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.3hi1214-584r · Cited by 123 · cited 1×
“[43,48,49], Th2 cells [43], ILC2s [50,51], macrophages [52,139], DCs [53], and mast cells [41].”
BackgroundSelf-citationThe role of prostaglandins in allergic lung inflammation and asthma
Claar, D., Hartert, T. V., & Peebles, R. S. (2015) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2015.992783 · Cited by 116
Innate effector cells in angiogenesis and lymphangiogenesis
Varricchi, G., Loffredo, S., Galdiero, M. R., Marone, G., Cristinziano, L., Granata, F., & Marone, G. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.05.002 · Cited by 116
Self-citation15-Deoxy-Δ12,1412,14-prostaglandins D2 and J2 Are Potent Activators of Human Eosinophils
Monneret, G., Li, H., Vasilescu, J., Rokach, J., & Powell, W. S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.7.3563 · Cited by 112
Schuligoi, R., Sturm, E., Luschnig, P., Konya, V., Philipose, S., Sedej, M., Waldhoer, M., Peskar, B. A., & Heinemann, A. (2010) · Pharmacology · doi:10.1159/000313836 · Cited by 110 · cited 1×
“Engagement of DP2 receptor results in the inhibitory G-protein (Gi) with subsequent increased intracellular calcium level and reduced adenylyl cyclase activity and intracellular cAMP concentration [40,57].”
BackgroundBöhm, E., Sturm, G. J., Weiglhofer, I., Sandig, H., Shichijo, M., McNamee, A., Pease, J. E., Kollroser, M., Peskar, B. A., & Heinemann, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310270200 · Cited by 110 · cited 1×
“[43,82,83] that play a role in different phenotypes of asthma [60,84,85].”
BackgroundPGD2/PTGDR2 Signaling Restricts the Self-Renewal and Tumorigenesis of Gastric Cancer
Zhang, B., Bie, Q., Wu, P., Zhang, J., You, B., Shi, H., Qian, H., & Xu, W. (2018) · Stem Cells · doi:10.1002/stem.2821 · Cited by 110 · cited 1×
“Moreover, PGD2 exerts antitumor effect on gastric cancer through the engagement of DP2 receptor [159].”
BackgroundHeinemann, A., Schuligoi, R., Sabroe, I., Hartnell, A., & Peskar, B. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.9.4752 · Cited by 108
Law, A. W., Reed, S. D., Sundy, J. S., & Schulman, K. A. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2003.68 · Cited by 105 · cited 1×
“and $6 billion for allergic rhinitis [3].”
The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma
Erpenbeck, V. J., Popov, T. A., Miller, D., Weinstein, S. F., Spector, S. L., Magnusson, B., Osuntokun, W., Goldsmith, P., Weiss, H., & Beier, J. (2016) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2016.06.005 · Cited by 105 · cited 1×
“Another phase II trial looked at FEV1 change in mild-to-severe adult asthmatic patients over 20 days [126].”
BackgroundT follicular helper (Tfh) cells in normal immune responses and in allergic disorders
Varricchi, G., Harker, J., Borriello, F., Marone, G., Durham, S. R., & Shamji, M. H. (2016) · Allergy · doi:10.1111/all.12878 · Cited by 104
Self-citationBateman, E. D., Guerreros, A. G., Brockhaus, F., Holzhauer, B., Pethe, A., Kay, R. A., & Townley, R. G. (2017) · European Respiratory Journal · doi:10.1183/13993003.00670-2017 · Cited by 104
Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459
Singh, D., Cadden, P., Hunter, M., Pearce Collins, L., Perkins, M., Pettipher, R., Townsend, E., Vinall, S., & O'Connor, B. (2013) · European Respiratory Journal · doi:10.1183/09031936.00092111 · Cited by 102 · cited 1×
“to bronchial allergy challenge demonstrated a significant reduction in late phase reaction and FEV1 compared to placebo [136].”
BackgroundTranscript profiling of CD 16‐positive monocytes reveals a unique molecular fingerprint
Frankenberger, M., Hofer, T. P. J., Marei, A., Dayyani, F., Schewe, S., Strasser, C., Aldraihim, A., Stanzel, F., Lang, R., Hoffmann, R., et al. (2012) · European Journal of Immunology · doi:10.1002/eji.201141907 · Cited by 95 · cited 1×
“type 2 (ILC2s) [50,51], macrophages [52], DCs [53], mast cells [41], monocytes [54], and Th2 cells [43].”
BackgroundSafety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients
Busse, W. W., Wenzel, S. E., Meltzer, E. O., Kerwin, E., Liu, M. C., Zhang, N., Chon, Y., Budelsky, A., Lin, J., & Lin, S. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.10.013 · Cited by 91 · cited 2×
“Similarly, the dual DP1/DP2 antagonist vidupiprant (AMG 853) provided no benefit as an add-on therapy to ICS in moderate-to-severe asthma [104].”
BackgroundEosinophils as a novel cell source of prostaglandin D2: autocrine role in allergic inflammation
Luna-Gomes, T., Magalhães, K. G., Mesquita-Santos, F. P., Bakker-Abreu, I., Samico, R. F., Molinaro, R., Calheiros, A. S., Diaz, B. L., Bozza, P. T., Weller, P. F., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101806 · Cited by 87 · cited 2×
“PGD2 is also elaborated by activated dendritic cells (DCs) [29], macrophages [30], eosinophils [31], T helper type 2 (Th2”
BackgroundEmergence of Biomolecular Pathways to Define Novel Asthma Phenotypes. Type-2 Immunity and Beyond
Wenzel, S. E. (2016) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0141ps · Cited by 86
Hall, I. P., Fowler, A. V., Gupta, A., Tetzlaff, K., Nivens, M. C., Sarno, M., Finnigan, H., Bateman, E. D., & Sutherland, E. R. (2015) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2015.03.003 · Cited by 85
Horak, F., Zieglmayer, P., Zieglmayer, R., Lemell, P., Collins, L. P., Hunter, M. G., Steiner, J., Lewis, T., Payton, M. A., Perkins, C. M., et al. (2012) · Allergy · doi:10.1111/all.12042 · Cited by 85 · cited 1×
“Interestingly, two DP2 antagonists, BI 671800 and OC 000459, have shown safety and efficacy in the treating SAR symptoms [120,145].”
BackgroundDiamant, Z., Sidharta, P. N., Singh, D., O'Connor, B. J., Zuiker, R. G. J. A., Leaker, B. R., Silkey, M., & Dingemanse, J. (2014) · Clinical & Experimental Allergy · doi:10.1111/cea.12357 · Cited by 85
Controversial role of mast cells in skin cancers
Varricchi, G., Galdiero, M. R., Marone, G., Granata, F., Borriello, F., & Marone, G. (2016) · Experimental Dermatology · doi:10.1111/exd.13107 · Cited by 85 · cited 1×
“Clinical phenotypes and biomarkers are required to select patients for novel biological therapies [151].”
BackgroundSelf-citationYoshimura-Uchiyama, C., Iikura, M., Yamaguchi, M., Nagase, H., Ishii, A. I., Matsushima, K., Yamamoto, K., Shichijo, M., Bacon, K. B., & Hirai, K. (2004) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2004.02027.x · Cited by 84
New targets for allergic rhinitis — a disease of civilization
Holgate, S. T., & Broide, D. H. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1224 · Cited by 84 · cited 1×
“Bronchial asthma and allergic rhinitis are common chronic clinical conditions that affect more than 30% of adults in industrialized societies [1,2].”
BackgroundJames, K. M., Gebretsadik, T. S., Escobar, G. J., Wu, P., Carroll, K. N., Li, S. X., Walsh, E. M., Mitchel, E. F., Sloan, C., & Hartert, T. V. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.01.009 · Cited by 81 · cited 1×
“are associated with the onset, progression, and acute exacerbations of asthma particularly in children [154,155].”
BackgroundThe contribution of mast cells to bacterial and fungal infection immunity
Piliponsky, A. M., & Romani, L. (2018) · Immunological Reviews · doi:10.1111/imr.12623 · Cited by 81 · cited 1×
“disorders [58–60], but are also involved in autoimmune disorders [61], microbial infections [62,63], cardiovascular diseases [64,65],”
BackgroundNantel, F., Fong, C., Lamontagne, S., Wright, D. H., Giaid, A., Desrosiers, M. Y., Metters, K. M., O’Neill, G. P., & Gervais, F. G. (2004) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2003.12.002 · Cited by 78 · cited 1×
“Finally, DP2 receptors are expressed on a subset of T cells in nasal mucosa of patients with allergic rhinitis [91].”
BackgroundActivated prostaglandin D2 receptors on macrophages enhance neutrophil recruitment into the lung
Jandl, K., Stacher, E., Bálint, Z., Sturm, E. M., Marić, J., Peinhaupt, M., Luschnig, P., Aringer, I., Fauland, A., Kónya, V., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.11.012 · Cited by 78 · cited 3×
“[43,48,49], Th2 cells [43], ILC2s [50,51], macrophages [52,139], DCs [53], and mast cells [41].”
BackgroundStubbs, V. E. L., Schratl, P., Hartnell, A., Williams, T. J., Peskar, B. A., Heinemann, Á., & Sabroe, I. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201803200 · Cited by 76 · cited 1×
“that PGD2 has no effect on human neutrophils and monocytes [44].”
BackgroundBasophils: Historical Reflections and Perspectives
Marone, G., Borriello, F., Varricchi, G., Genovese, A., & Granata, F. (2014) · Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy · doi:10.1159/000358734 · Cited by 68
Self-citationMast cells in rheumatoid arthritis: friends or foes?
Rivellese, F., Nerviani, A., Rossi, F. W., Marone, G., Matucci‐Cerinic, M., de Paulis, A., & Pitzalis, C. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.04.001 · Cited by 68 · cited 1×
“disorders [58–60], but are also involved in autoimmune disorders [61], microbial infections [62,63], cardiovascular diseases [64,65],”
BackgroundSelf-citationTwo Phase II randomized trials on the CRTh2 antagonist AZD1981 in adults with asthma
Kuna, P., Bjermer, L. H., & Tornling, G. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s105142 · Cited by 65 · cited 1×
“AZD1981 (AstraZeneca) is an oral, selective PD2 receptor antagonist evaluated in two phase IIa studies in patients with asthma [118].”
BackgroundSykes, D. A., Bradley, M. E., Riddy, D., Willard, E. G., Reilly, J., Miah, A., Bauer, C., Watson, S. J., Sandham, D. A., Dubois, G. R., et al. (2016) · Molecular Pharmacology · doi:10.1124/mol.115.101832 · Cited by 64 · cited 2×
“, IL-5, IL-13) from human CD4 Th2 lymphocytes [123].”
BackgroundPettipher, R., Vinall, S. L., Xue, L., Speight, G., Townsend, E. R., Gazi, L., Whelan, C. J., Armer, R. E., Payton, M. A., & Hunter, M. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.187203 · Cited by 63 · cited 1×
“and orally active DP2 receptor antagonist that inhibits PGD2 activation of T helper lymphocytes and eosinophils [134].”
BackgroundRole of Prostaglandin D2 and Its Receptors in the Pathophysiology of Asthma
Oguma, T., Asano, K., & Ishizaka, A. (2008) · Allergology International · doi:10.2332/allergolint.08-rai-0033 · Cited by 61 · cited 1×
“Activation of DP1 receptor increases adenylyl cyclase activity with subsequent production of cyclic adenosine monophosphate (cAMP) [41] and protein kinase A activation [42].”
BackgroundPGD2/DP2 receptor activation promotes severe viral bronchiolitis by suppressing IFN- λ production
Werder, R. B., Lynch, J. P., Simpson, J., Zhang, V., Hodge, N. H., Poh, M., Forbes‐Blom, E., Kulis, C., Smythe, M. L., Upham, J. W., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao0052 · Cited by 61 · cited 1×
“upregulated PGD2 synthase and increased PGD2 release from human airway epithelial cells [156].”
BackgroundStinson, S., Amrani, Y., & Brightling, C. E. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.08.027 · Cited by 58
Krug, N., Gupta, A., Badorrek, P., Koenen, R., Mueller, M., Pivovarova, A., Hilbert, J., Wetzel, K., Hohlfeld, J. M., & Wood, C. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.10.013 · Cited by 57 · cited 2×
“Interestingly, two DP2 antagonists, BI 671800 and OC 000459, have shown safety and efficacy in the treating SAR symptoms [120,145].”
BackgroundExpression of DP2 (CRTh2), a Prostaglandin D2 Receptor, in Human Mast Cells
Moon, T. C., Campos‐Alberto, E., Yoshimura, T., Bredo, G., Rieger, A. M., Puttagunta, L., Barreda, D. R., Befus, A. D., & Cameron, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108595 · Cited by 57 · cited 5×
“type 2 (ILC2s) [50,51], macrophages [52], DCs [53], mast cells [41], monocytes [54], and Th2 cells [43].”
BackgroundInfluentialGervais, F. G., Sawyer, N., Stocco, R., Hamel, M., Krawczyk, C. M., Sillaots, S., Denis, D., Wong, E., Wang, Z., Gallant, M., et al. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.068585 · Cited by 54 · cited 1×
“MK-7246 is a potent, selective and oral DP2 receptor antagonist [129,130].”
BackgroundClinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis
Philip, G., van Adelsberg, J., Loeys, T., Liu, N., Wong, P., Lai, E., Dass, S. B., & Reiss, T. F. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.07.006 · Cited by 53 · cited 1×
“However, laropiprant did not demonstrate efficacy in patients with SAR or asthma [103] and”
BackgroundChildhood asthma clusters reveal neutrophil‐predominant phenotype with distinct gene expression
Su, M., Lin, W., Tsai, C., Chiang, B., Yang, Y., Lin, Y., Wang, L., Lee, J., Chou, C. ‐., Wu, Y., et al. (2018) · Allergy · doi:10.1111/all.13439 · Cited by 53 · cited 1×
“or neutrophils-predominant inflammation [153].”
Monneret, G., Boumiza, R., Gravel, S., Cossette, C., Bienvenu, J., Rokach, J., & Powell, W. S. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.074823 · Cited by 50
Personalized Medicine in Allergy
Ferrando, M., Bagnasco, D., Varricchi, G., Bernardi, S., Bragantini, A., Passalacqua, G., & Canonica, G. W. (2016) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2017.9.1.15 · Cited by 50 · cited 2×
“, inhaled β2-agonists and ICS), effective in the vast majority of patients, does not control a significant percentage (≅ 10%) of severe asthmatics [140].”
BackgroundSelf-citationDiscovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases
Gallant, M., Beaulieu, C., Berthelette, C., Colucci, J. T., Crackower, M. A., Dalton, C. R., Denis, D., Ducharme, Y., Friesen, R. W., Guay, D., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.11.015 · Cited by 49 · cited 1×
“MK-7246 is a potent, selective and oral DP2 receptor antagonist [129,130].”
BackgroundImportant and specific role for basophils in acute allergic reactions
Korošec, P., Gibbs, B. F., Rijavec, M., Čustović, A., & Turner, P. (2018) · Clinical & Experimental Allergy · doi:10.1111/cea.13117 · Cited by 49 · cited 1×
“cells, basophils and their mediators are also involved in allergic disorders [60,68].”
BackgroundPharmacokinetics, Pharmacodynamics, and Safety of a Prostaglandin D2 Receptor Antagonist
Lai, E., Wenning, L., Crumley, T., Lepeleire, I. D., Liu, F., de Hoon, J., Hecken, A. V., Depré, M., Hilliard, D., Greenberg, H. E., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100345 · Cited by 48 · cited 1×
“Laropiprant (previously referred to as MK-0524) is a selective and potent DP1 antagonist [102].”
BackgroundXue, L., Barrow, A., & Pettipher, R. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2008.03871.x · Cited by 48
Therapeutic interventions in severe asthma
Canonica, G. W., Senna, G., Mitchell, P. D., O’Byrne, P. M., Passalacqua, G., & Varricchi, G. (2016) · World Allergy Organization Journal · doi:10.1186/s40413-016-0130-3 · Cited by 47 · cited 1×
“acting β2-adrenergic agonists, 5–10% are refractory to conventional treatments and often experience frequent exacerbations [4].”
BackgroundSelf-citationWang, Y.-H., Trucksis, M., McElwee, J. J., Wong, P. H., Maciolek, C. M., Thompson, C. D., Prueksaritanont, T., Garrett, G. C., Declercq, R., Vets, E., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.20 · Cited by 46 · cited 1×
“a highly variable pharmacokinetics due to genetic polymorphisms and extensive first-pass metabolism [133].”
BackgroundProstaglandin D Synthase in Human Megakaryoblastic Cells
Mahmud, I., Ueda, N., Yamaguchi, H., Yamashita, R., Yamamoto, S., Kanaoka, Y., Urade, Y., & Hayaishi, O. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.45.28263 · Cited by 44 · cited 2×
“PGD2 can also be produced by activated Th2 cells [32], DCs [29], macrophages [30], eosinophils [31], endothelial cells [33,34], and platelets [35,36].”
BackgroundNorman, P. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.839658 · Cited by 42
Immunopharmacological modulation of mast cells
Borriello, F., Granata, F., Varricchi, G., Genovese, A., Triggiani, M., & Marone, G. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.07.002 · Cited by 40 · cited 1×
“[43,82,83] that play a role in different phenotypes of asthma [60,84,85].”
BackgroundSelf-citationEffect of prostaglandin D2 in modulating histamine release from human basophils.
Peters, S. P., Kagey-Sobotka, A., MacGlashan, D. W., & Lichtenstein, L. M. (1984) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21724-4 · Cited by 39 · cited 2×
“PGD2 enhances human basophil histamine release induced by immunologic stimuli and also reverses the inhibition of mediator release induced by drugs that increase cAMP [69].”
BackgroundChu, C., Wei, H., Zhu, W., Shen, Y., & Xu, Q. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx044 · Cited by 37 · cited 1×
“PGD2 levels are decreased in the plasma of depressive disorder patients and in the brain of depressive mice [160].”
BackgroundSantus, P., & Radovanovic, D. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1212838 · Cited by 37
Role of biologics targeting type 2 airway inflammation in asthma: what have we learned so far?
Parulekar, A. D., Diamant, Z., & Hanania, N. A. (2016) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000343 · Cited by 36
Unilateral nasal allergen challenge leads to bilateral release of prostaglandin D2
Wagenmann, M., Baroody, F. M., Desrosiers, M. Y., Hubbard, W. C., FORD, S., Lichtenstein, L. M., & Naclerio, R. M. (1996) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.1996.tb00552.x · Cited by 33
van Hecken, A., Depré, M., Lepeleire, I. D., Thach, C. T., Oeyen, M., Effen, J. V., Laethem, T., Mazina, K. E., Crumley, T. M., Wenning, L. A., et al. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0211-2 · Cited by 33 · cited 2×
“Intranasal administration of PGD2 mimics symptoms of patients with allergic rhinitis [90].”
BackgroundDiscovery of AMG 853, a CRTH2 and DP Dual Antagonist
Liu, J., Li, A., Wang, Y., Johnson, M. G., Su, Y., Wang, S., Wang, X., Lively, S. E., Brown, M., Lai, S., et al. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml1002234 · Cited by 33 · cited 1×
“Vidupiprant (AMG-853, Amgen) is a potent, dual DP1 and DP2 receptor antagonist with a 25-fold higher affinity for the latter receptor [138].”
BackgroundHorak, F., Toth, J., Hirschwehr, R., Marks, B., Stübner, U. P., Jäger, S., Berger, U., Schleinzer, K., & Günczler, P. (1998) · Allergy · doi:10.1111/j.1398-9995.1998.tb03775.x · Cited by 33
Ratner, P. H., Andrews, C. P., Hampel, F. C., Martin, B. G., Mohar, D. E., Bourrelly, D., Danaietash, P., Mangialaio, S., Dingemanse, J., Hmissi, A., et al. (2017) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-017-0183-z · Cited by 33 · cited 1×
“of dose-related efficacy of setipiprant in patients with SAR, but these findings were not confirmed in subsequent phase II and phase III trials [107].”
ResultAre Basophils and Mast Cells Masters in HIV Infection?
Marone, G., Varricchi, G., Loffredo, S., Galdiero, M. R., Rivellese, F., & de Paulis, A. (2016) · International Archives of Allergy and Immunology · doi:10.1159/000452889 · Cited by 32 · cited 1×
“cancer [66], and immunodeficiencies [67].”
Self-citationVirgolini, I. J., Li, S., Sillaber, C., Majdic, O., Sinzinger, H. F., Lechner, K., Bettelheim, P., & Valent, P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42333-2 · Cited by 30
Fevipiprant in the treatment of asthma
White, C., Wright, A. K. A., & Brightling, C. E. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1432592 · Cited by 28
Hirahara, K., Mato, N., Hagiwara, K., & Nakayama, T. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr1117-456r · Cited by 25 · cited 1×
“asthma [27,28], induce PGD2 production from human mast cells [24].”
BackgroundProstaglandin D2 Receptor CRTH2 Antagonists for the Treatment of Inflammatory Diseases
Chen, J. J., & Budelsky, A. (2011) · Progress in medicinal chemistry · doi:10.1016/b978-0-12-381290-2.00002-1 · Cited by 24
Bain, G., Lorrain, D. S., Stebbins, K. J., Broadhead, A. R., Santini, A. M., Prodanovich, P., Darlington, J. V., King, C. D., Lee, C., Baccei, C. S., et al. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.180430 · Cited by 24 · cited 1×
“PD2 antagonist effective in a guinea pig model of albumininduced allergic rhinitis [111].”
BackgroundErpenbeck, V. J., Vets, E., Gheyle, L., Osuntokun, W., Larbig, M., Neelakantham, S., Sandham, D. A., Dubois, G. R., Elbast, W., Goldsmith, P., et al. (2015) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.244 · Cited by 24 · cited 2×
“In a phase I single-dose, single-center study fevipiprant showed a favorable safety profile in healthy subjects [124].”
BackgroundRole of prostaglandin D 2 and CRTH 2 blockade in early‐ and late‐phase nasal responses
Shiraishi, Y., Takeda, K., Domenico, J. M., & Gelfand, E. W. (2014) · Clinical & Experimental Allergy · doi:10.1111/cea.12280 · Cited by 23
Are emerging PGD2 antagonists a promising therapy class for treating asthma?
Farne, H. A., Jackson, D. J., & Johnston, S. L. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1244262 · Cited by 23
Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations
Bagnasco, D., Ferrando, M., Caminati, M., Bragantini, A., Puggioni, F., Varricchi, G., Passalacqua, G., & Canonica, G. W. (2017) · Drug Safety · doi:10.1007/s40264-017-0522-5 · Cited by 23 · cited 1×
“The above findings imply that a phenotyping approach is necessary to identify patient subgroups candidate to targeted therapies [143,150].”
BackgroundSelf-citationTakahashi, G., Asanuma, F., Suzuki, N., Hattori, M., Sakamoto, S. X., Kugimiya, A., Tomita, Y., Kuwajima, G., Abraham, W. M., Deguchi, M., et al. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.08.003 · Cited by 22 · cited 12×
“In this randomized, double-blind, placebo controlled, partial-crossover study, adults with SAR were exposed to out-of-season allergen challenge.”
BackgroundInfluentialSandham, D. A., Arnold, N., Aschauer, H., Bala, K., Barker, L., Brown, L., Brown, Z., Budd, D. C., Cox, B. J., Docx, C. J., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.08.025 · Cited by 22 · cited 2×
“NVP-QAV680 (Novartis) is a potent and selective DP2 receptor antagonist that inhibits human eosinophil shape change (ESC) and PGD2 induced-pulmonary eosinophilia in rats [18].”
BackgroundInduction of Hematopoietic Prostaglandin D Synthase in Human Megakaryocytic Cells by Phorbol Ester
Suzuki, T., Watanabe, K., Kanaoka, Y., Sato, T., & Hayaishi, O. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7803 · Cited by 22 · cited 2×
“PGD2 can also be produced by activated Th2 cells [32], DCs [29], macrophages [30], eosinophils [31], endothelial cells [33,34], and platelets [35,36].”
BackgroundInvestigational prostaglandin D2receptor antagonists for airway inflammation
Santini, G., Mores, N., Malerba, M., Mondino, C., Macis, G., & Montuschi, P. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1175434 · Cited by 22
Prostaglandin D2 generation from human lung mast cells is catalysed exclusively by cyclooxygenase-1
Baothman, B. K., Smith, J., Kay, L. J., Suvarna, S. K., & Peachell, P. T. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.12.005 · Cited by 21 · cited 1×
“In human lung mast cells prostaglandin D2 (PGD2) is a major metabolite of COX-1 pathway [20].”
BackgroundGéhin, M., Strasser, D. S., Zisowsky, J., Farine, H., Groenen, P. M. A., Dingemanse, J., & Sidharta, P. N. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.478 · Cited by 18 · cited 1×
“The setipiprant back-up compound ACT-453859 (Actelion) is in phase I clinical development for cardiovascular disorders [108] and it is unknown whether it”
BackgroundOkubo, K., Hashiguchi, K., Takeda, T., Baba, K., Kitagoh, H., Miho, H., Tomomatsu, H., Yamaguchi, S., Odani, M., & Yamamotoya, H. (2017) · Allergy · doi:10.1111/all.13174 · Cited by 18 · cited 2×
“Some DP1 antagonists have been shown efficacy in a variety of animal models of rhinitis [100] and in SAR [101].”
BackgroundMauser, P. J., House, A., Jones, H., Correll, C. C., Boyce, C. W., & Chapman, R. W. (2013) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2013.03.005 · Cited by 17
Bain, G., King, C. D., Brittain, J., Hartung, J. P., DeArmond, I., Stearns, B. A., Truong, Y. P., Hutchinson, J. H., Evans, J. F., & Holme, K. R. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011421912 · Cited by 17
Effect of prostaglandin D2 on VEGF release by nasal polyp fibroblasts
Kanai, K., Okano, M., Fujiwara, T., Kariya, S., Haruna, T., Omichi, R., Makihara, S., Hirata, Y., & Nishizaki, K. (2016) · Allergology International · doi:10.1016/j.alit.2016.03.003 · Cited by 15 · cited 2×
“DP2 receptor is also expressed on bronchial epithelial cells of asthmatics [55] and on nasal polyp fibroblasts [56].”
BackgroundWenzel, S. E., Hopkins, R., Saunders, M., Chantry, D., Anderson, L., Aitchison, R., Eberhardt, C., Bell, S. J., Cole, J., Wolfe, J. D., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.12.037 · Cited by 14 · cited 1×
“initially reported and subsequently retracted [115].”
Calbet, M., Andrés, M., Armengol, C., Bravo, M., Eichhorn, P., López, R., García‐González, V., Roberts, R. S., & Miralpeix, M. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.06.014 · Cited by 14 · cited 1×
“LAS191859 (Almirall) is a potent, selective and long-lasting DP2 receptor antagonist [128].”
BackgroundGil, M. A., Caniga, M., Woodhouse, J. D., Eckman, J. B., Lee, H., Salmon, M., Naber, J. R., Hamilton, V. T., Sevilla, R. S., Bettano, K. A., et al. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.09.021 · Cited by 13
Hirano, Y., Shichijo, M., Ikeda, M., Kitaura, M., Tsuchida, J., Asanuma, F., Yanagimoto, T., Furue, Y., Imura, K., Yasui, K., et al. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.05.003 · Cited by 11
Fowler, A., Koenen, R., Hilbert, J., Blatchford, J., Kappeler, D., Benediktus, E., Wood, C. C., & Gupta, A. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.947 · Cited by 11
Tasaki, M., Kobayashi, M., Tenda, Y., Tsujimoto, S., Nakazato, S., Numazaki, M., Hirano, Y., Matsuda, H., Terasaka, T., Miyao, Y., et al. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.04.017 · Cited by 10
Nagira, Y., Goto, K., Tanaka, H., Aoki, M., Furue, S., Inagaki, N., Tomita, Y., & Shichijo, M. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.231225 · Cited by 8 · cited 1×
“to various stimuli, including histamine [92].”
Effects of intensity of early response to allergen on the late phase of both the nose and skin.
Small, P., Biskin, N., & Barrett, D. (1994) · PubMed · Cited by 8
Nagata, N., Iwanari, H., Kumagai, H., Kusano‐Arai, O., Ikeda, Y., Aritake, K., Hamakubo, T., & Urade, Y. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175452 · Cited by 8 · cited 1×
“Interestingly, a blocking mAb against an extracellular domain of mouse DP2 has been characterized [105].”
BackgroundA novel DP2receptor antagonist (AM-461): a patent evaluation of WO2011085033
Norman, P. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.636738 · Cited by 6
Research works printed but not linked: 8
- Fuller RW, 1986, Am Rev Respir Dis, 133, 252
- Schulman ES, 1981, Am Rev Respir Dis, 124, 402
- Small P, 1994, Ann Allergy, 73, 252
- Singh D, 2017, Clin Pharmacol, 9, 165
- Fitzgerald MF, 2013, Am J Respir Crit Care Med, 187, A2617
- Fitzgerald M, 2013, ATS Conference Proceedings, Pennsylvania, A3874
- Bell S, 2012, Am J Respir Crit Care Med, 185, A2756
- Petsky HL, 2017, Cochrane Database Syst Rev, 8, CD005603
Cited by
Lactate modulation of immune responses in inflammatory versus tumour microenvironments
Certo, M., Tsai, C.-H., Pucino, V., Ho, P.-C., & Mauro, C. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-0406-2 · Cited by 924
Self-citationAtopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623
Biologics and airway remodeling in severe asthma
Varricchi, G., Ferri, S., Pepys, J., Poto, R., Spadaro, G., Nappi, E., Paoletti, G., Virchow, J. C., Heffler, E., & Canonica, W. G. (2022) · Allergy · doi:10.1111/all.15473 · Cited by 254
Self-citationEicosanoid signalling blockade protects middle-aged mice from severe COVID-19
Wong, L.-Y. R., Zheng, J., Wilhelmsen, K., Li, K., Ortiz, M. E., Schnicker, N. J., Thurman, A., Pezzulo, A. A., Szachowicz, P. J., Li, P., et al. (2022) · Nature · doi:10.1038/s41586-022-04630-3 · Cited by 178
The Intriguing Role of Interleukin 13 in the Pathophysiology of Asthma
Marone, G., Granata, F., Pucino, V., Pecoraro, A., Heffler, E., Loffredo, S., Scadding, G. W., & Varricchi, G. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01387 · Cited by 171
Self-citation
Metadata
- Authors
- Marone, G., Galdiero, M. R., Pecoraro, A., Pucino, V., Criscuolo, G., Triassi, M., & Varricchi, G.
- Affiliations
- Ospedale Monaldi (IT)
- University of Naples Federico II (IT)
- Queen Mary University of London (GB)
- Corresponding author
- Varricchi, Gilda
- ORCID
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2018-12-07
- Volume
- 28
- Issue
- 1
- Pages
- 73-84
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2902819785
- Cited by
- 62
- References
- 153
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 5 · 2023: 4 · 2022: 12 · 2021: 15 · 2020: 9 · 2019: 10
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Investigational Drugs (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Funders
- Regione Campania CISI-Lab Project, CRèME Projec, and TIMING Project
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Keywords
- prostaglandin D2, CRTH2, allergic rhinitis, asthma, allergic inflammation, mast cells, drug safety, drug efficacy
- MeSH terms
- Adult, Animals, Asthma, Child, Humans, Mast Cells, Receptors, Immunologic, Receptors, Prostaglandin, Drug Design, Prostaglandin D2, Anti-Allergic Agents, Rhinitis, Allergic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.